Lanreotide autogel is a therapeutic option for patients who develop acute pancreatitis after somatostatin analog treatment

• Published in: Journal of endocrinological investigation Vol. 27; no. 6; pp. 613 - 614
• Main Authors: Boix, E, López, P, Pérez-Mateo, M, Picó, A
• Format: Journal Article
• Language: English
• Published: Italy 01.06.2004
• Subjects: Acute Disease; Adenoma - drug therapy; Adult; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Female; Hormones - adverse effects; Hormones - therapeutic use; Humans; Pancreatitis - chemically induced; Pancreatitis - drug therapy; Peptides, Cyclic - administration & dosage; Peptides, Cyclic - therapeutic use; Pituitary Neoplasms - drug therapy; Somatostatin - administration & dosage; Somatostatin - adverse effects; Somatostatin - analogs & derivatives; Somatostatin - therapeutic use